Business
Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available
FRAMINGHAM, MA / ACCESSWIRE / February 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"FRAMINGHAM, MA / ACCESSWIRE / February 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that the webcast replay from the presentation given by Jeffrey Eisenberg, Chief Executive Officer of Xenetic, at NobleCon16 - Noble Capital Markets' 16th Annual Investor Conference is now available.The high-definition, video webcast of the Company's presentation is accessible here, and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: www.nobleconference.com and on Channelchek www.channelchek.com, the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website and on the Channelchek website for 90 days.About Xenetic BiosciencesXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal...